TRACON to Report Second Quarter 2015 Company Highlights and Financial Results on August 5, 2015
Conference call and webcast: | |
Date: | August 5, 2015 |
Time: | 4:30 pm Eastern Daylight Time (1:30 pm Pacific Daylight Time) |
Dial-in: | (855) 779-9066 (Domestic) or (631) 485-4859 (International) |
Passcode: | 93406510 |
Via web: | www.traconpharma.com; "Events and Presentation" section within the "Investors" section |
A replay of the webcast will be available for 60 days on the website.
About TRACON
TRACON develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. TRACON's current pipeline includes two clinical stage product candidates: TRC105, an anti-endoglin antibody that is being developed for the treatment of renal cell carcinoma, soft tissue sarcoma, hepatocellular carcinoma, glioblastoma and choriocarcinoma, and TRC102, a small molecule that is being developed for the treatment of lung cancer and glioblastoma. To learn more about TRACON and its product candidates, visit TRACON's website at www.traconpharma.com.
CONTACT: Company Contact:Casey Logan Chief Business Officer (858) 550-0780 ext. 236 clogan@traconpharma.com Investor Contact:Andrew McDonald LifeSci Advisors LLC 646-597-6987 Andrew@lifesciadvisors.com